HCV assay

Details for Australian Patent Application No. 2003273296 (hide)

Owner Novartis Vaccines and Diagnostics, Inc.

Inventors Arcangel, Phillip; Chien, David

Agent FB Rice

Pub. Number AU-B-2003273296

PCT Number PCT/US03/28071

PCT Pub. Number WO2004/021871

Priority 60/409,515 09.09.02 US

Filing date 8 September 2003

Wipo publication date 29 March 2004

Acceptance publication date 26 November 2009

International Classifications

C07K 14/18 (2006.01) Peptides having more than 20 amino acids

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

C12Q 1/70 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving virus or bacteriophage

G01N 33/549 (2006.01) Investigating or analysing materials by specific methods not covered by groups

G01N 33/576 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for hepatitis

Event Publications

5 February 2004 Complete Application Filed

  Priority application(s): 60/409,515 09.09.02 US

13 May 2004 Application Open to Public Inspection

  Published as AU-B-2003273296

10 July 2008 Assignment before Grant

  Chiron Corporation The application has been assigned to Novartis Vaccines and Diagnostics, Inc. 2004

5 November 2009 Alteration of Name

  The name of the applicant has been altered to Novartis Vaccines and Diagnostics, Inc.

26 November 2009 Application Accepted

  Published as AU-B-2003273296

25 March 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003273297-LONG ACTING ERYTHROPOIETINS THAT MAINTAIN TISSUE PROTECTIVE ACTIVITY OF ENDOGENOUS ERYTHROPOIETIN

2003273295-1, 4, 5-substituted 1, 2-dihydro-pyrazol-3-one and 3-alkoxy-1H-pyrazole derivatives S TNF-alpha and interleukin lowering agents for the treatment of inflammations